Human islet cells (Alpha, beta, PP, delta and epsilon cells) in cultured in the lab with GLP1 do not undergo cell death as often as control cells (Farilla et al, 2003)
GLP-1 medications are approved for adults who have a body mass index (BMI) of 30 or higher, or a BMI of at least 27 plus a weight-related medical condition, such as the following: Type 2 diabetes High blood pressure High cholesterol Obstructive sleep apnea Cardiovascular disease that increases the risk of heart attack or stroke MASH, or metabolic dysfunctionassociated steatohepatitis, a form of liver inflammation Avlin Imaeda, MD, PhD, a Yale Medicine gastroenterologist who is board-certified in obesity medicine, notes that qualifying for the medication based on heart disease aloneoften necessary for insurance coveragecan be challenging
Eli Lilly), a dual GLP-1 and GIP receptor agonist, for 52 weeks
Why is Lipo C administered subcutaneously instead of intramuscularly
What about differentiated thyroid cancer
cellular health*